Pipeline Watch: Phase III Starts With Plinabulin, Rova-T And Relugolix
Executive Summary
Pipeline Watch is Scrip's weekly update on the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
You may also be interested in...
Janssen's Tremfya Gains Psoriatic Arthritis Indication In EU
The European Commission has extended the indications for Janssen’s Tremfya to include psoriatic arthritis, and those for BMS’s Opdivo to include gastroesophageal cancer.
Genmab Accelerates Priority Candidates, Ends Enapotamab Vedotin Development
Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.
Pipeline Watch: Phase III Readouts In Liver Diseases, COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Need a specific report? 1000+ reports available
Buy Reports